Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Higher IL-21 levels may help predict alopecia areata activity.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Higher androgen levels are linked to more severe hair growth in hirsute women.

Carcinosin, a homeopathic remedy, helped a young girl with alopecia areata regrow hair and reduce psychological symptoms.

More lesions mean more severe alopecia areata.

Lower vitamin D levels are linked to more severe alopecia areata.

Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.

People with lower levels of free testosterone tend to have worse COVID-19 outcomes.

Higher MPV and CRP levels may indicate more severe alopecia areata.

There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.

Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

STS01 1% effectively promotes hair regrowth with minimal side effects.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib may help treat severe hair loss, but more research is needed.

Baricitinib is effective and safe for treating severe alopecia areata.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

COVID-19 doesn't make alopecia areata worse.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.